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Abstract  
The majority of anti-HIV drug susceptibility tests have been performed on subtype B HIV-1 strains, since these are the most prevalent in countries 
designing, testing, and manufacturing the current anti-HIV agents. The increasing global spread of HIV subtype highlights the need to determine 
the activity of anti-HIV drugs against subtypes of HIV other than subtype B. Furthermore an increasing number of individuals infected with many of 
the non subtype B virus strains now receive antiretroviral therapy because of rollout programs in developing countries as well as increasing 
migration to the developed world. The phenotypic susceptibility of two laboratory strains HIV-1JFRL and HIV-1IIIB (representing subtype B) and 
two clinical isolates HIV-104RTA and HIV-1025RTA (representing subtypes A and D respectively) was determined. The in vitro drug susceptibility testing 
of the isolates was carried out in C8166 cell line and in peripheral blood mononuclear cells (PBMCs). The study revealed that the drugs used in the 
Kenyan national ART program inhibited HIV-1 replication in-vitro as their inhibitory concentrations (IC50) compared well with the standard 
Inhibitory concentration values. The results also suggest a biochemical similarity of the reverse transcriptase (RT) and protease enzymes from 
these subtypes despite the divergence at the genetic level. The findings suggest that similar clinical benefits of antiviral therapy obtain in persons 
infected with other subtypes of HIV-1other than subtype B and that the generic drugs used in the national ART program in Kenya are as 
efficacious as branded drugs in inhibiting HIV replication in vitro despite the limited number of the viruses studied. 
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Antiretroviral drug design, resistance research, and interpretation 
systems have been largely based on HIV-1 subtype B viruses, which 
have historically been the most prevalent subtype in North America, 
Western Europe and Australia even though subtype B viruses 
account for only about 12% of the worldwide HIV-1 infections. 
Subtype C viruses are the most prevalent, accounting for about 
50% of cases [1]. Despite this diversity and prevalence, non-
subtype B (NSB) viruses remain largely uncharacterized [2]. An 
increasing number of individuals who are infected with many of the 
non– subtype B virus strains now receive antiretroviral therapy 
because of rollout programs in the resource-limited world and 
because of increasing migration to the developed world, particularly 
to countries in Europe. In Kenya approximately 500,000 adults and 
40,000 children were on ART by end of 2011[3]. 
  
Currently, there are 6 classes of ARV agents with 25 drugs approved 
for single drug treatment and 12 as fixed dose combinations (FDCs) 
by the United States food and drugs administration US-FDA [4]. 
These drugs target 4 distinct proteins namely; host cell receptor, 
reverse transcriptase, integrase and protease to retard HIV 
replication. The conventional classes of ARVs are nucleoside reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) and protease inhibitor (PIs). The 
target of NNRTIs is the same as NRTIs (viral reverse transcriptase). 
They inhibit HIV-1 RT by binding and inducing the formation of a 
hydrophobic pocket proximal to, but not overlapping the active site 
[5] Protease inhibitors (PIs) the third class of approved ARVs 
function by blocking proteolysis of the viral polyprotein, a step 
required for the production of infectious viral particles [6]. In the 
presence of a PI, only defective viral particles, unable to infect new 
cells, are produced. PIs are used in combination with two nRTIs as 
part of initial ART. Because they have limited bioavailability, they 
are co-administered with a pharmacologic “booster”, a low and 






Test compounds and viruses 
  
Five drugs used in the national ART programme namely AZT, ABC, 
EFV, LPV/r, and NVP/3TC/d4T were obtained from the Liverpool VCT 
Care and Treatment, a comprehensive care and treatment Centre in 
Nairobi in tablets form. Clinical isolates HIV-1 04RTA and HIV-
1025RTA (Genebank ascension numbers JF829686/A1 and JF829689/D 
respectively) were sourced from the Centre for virus research HIV 
laboratory strains bank. 
  
Drug susceptibility assays 
  
For CXCR4 Viruses (HIV-1IIIB, HIV-104RTA and HIV-1025 RTA) 
  
Antiviral assays were performed as previously described [8] with 
some modification. Briefly, C8166 cells growing in the logarithmic 
phase were inoculated with viral stock (HIV-1IIIB, HIV-104RTA and 
HIV-1 025RTA) at a MOI of 0.001 and incubated at 37°C in a 
CO2 incubator for 1h followed by washing in PBS. The cells were 
plated (1 ×105/ml) in the absence or presence of ARVs prepared in 
5 fold serial dilutions in culture medium and DMSO in a final volume 
of 200μl. Control wells containing cells and virus were co incubated 
on each plate. After a 3-5day incubation the wells were checked for 
signs of syncytium each day and once detected in control wells with 
no drugs, the supernatants were harvested and tested for viral 
growth using an ELISA specific for the P24 antigen of HIV-1 
(Biomereaux, France) as described by the manufacturer. The 
percentage inhibition of viral growth compared with control wells 
without drugs was calculated. The IC50 was determined from the 
dose response curves generated. All experiments were performed at 
least twice and mean percentage inhibition determined by the 
formulae; 
  
% Suppression = (Control P24 (pg/ml) – Test P24 (pg/ml) x 
100)/Control P24 (pg/ml) 
  
Anti-HIV-1 assay for JRFL strain (R5) 
  
The antiviral assay was performed as previously described by Japour 
et al [9] with some modifications. PBMCs from healthy donors were 
obtained by density gradient centrifugation using ficol paque 
(Amersham Biosciences, Sweden). PBMCs obtained were washed 3 
times in PBS and cell count done using the trypan blue dye 
exclusion test. The PBMCs were pelleted in a 50 ml falcon tube and 
held in the incubator for 3 hours for virus adsorption to take place; 
they were then washed in PBS. The cell pellet was re suspended in 
fresh complete RPMI 1640 medium supplemented with 50 U/ml 
human recombinant IL-2 (Gibco, USA) and seeded into the 96 well 
microtitre plate at a concentration of 105 cells /ml. Medium was 
added to duplicate wells up to a volume of 200µl/well and plate 
incubated. On day 4 half the medium was removed from the wells 
and replaced with same volume of fresh stimulated PBMCs 
containing the same concentration of the drugs as originally used. 
On day 7, supernatants from wells were harvested and production 
of HIV P24 both in the well with the test compounds as well as the 
control culture quantitatively determined by reading the absorbance 
at 490nm/630nm in the ELISA reader following the manufacturers’ 
instructions. HIV suppression was calculated using the formulae 
shown above. 
  
MTT cytotoxicity assay 
  
The cellular toxicity of compounds on C8166 cells was assessed by 
MTT colorimetric assay as described previously [10]. Briefly, 100ul 
of C8166 cells (1x 105/ml) were seeded on a 96 well microtiter plate 
and 100ul of various concentrations of the test compounds were 
added. The plate was incubated at 370C in a humidified CO2 
incubator for 72 h. 100µl of the cell supernatant was discarded from 
each well and 20ul of MTT reagent (Roche, Indianapolis USA) was 
added and incubated for 4h, followed by 100µl of solubilization 
buffer to dissolve the formazan crystals. After the crystals were 
dissolved completely, the plates were read on an ELISA reader (Lab 
systems, USA) at 540nm. The percentage cell viability (CV) was 
calculated manually from absorbance values using the formula: 
  
CV = (Average absorbance of duplicate drug wells x 100)/Average 
absorbance of control wells 
  
A dose-response curve was plotted to enable the calculation of the 






The 50% inhibitory concentrations (IC50) of ARVs against all the 
HIV-1 strains were derived from the respective susceptibility curves 
(Figure 1). The ARVS exhibited inhibitory activity against the two 
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HIV-1 clinical isolates and the two laboratory strains with the IC50 
ranging from 0.02 to 0.2 µg/ml within the normal ranges as 
previously reported [10]. The five ARVs exhibited a concentration 
dependent inhibition of HIV-1 in the two laboratory strains as well 
as in the two clinical isolates cytopathogenicity in C8166 cells. The 
50% antiviral inhibitory concentration (IC50) of the ARVs is shown 
on Figure 1. The ARVs also Inhibited cytopathic effect (CPE) on 






The antiviral activity of drugs can vary greatly because of factors 
such as genetic variation in isolates, host cell type, and multiplicity 
of infection assay used for measurement of virus replication. 
Because of genetic variation, determination of antiviral activity 
against a broad spectrum of viruses of well-characterized HIV 
laboratory strains and clinical isolates sufficient to assess the 
breadth of antiviral activity is recommended. In a previous study 
clade D viruses were reported to function with diminished drug 
sensitivity owing to rapid growth kinetics, whereas subtypes A, B, C 
and E demonstrated comparable sensitivity [12]. In the current 
study no decrease in sensitivity to AZT, Efavirenze, Abacavir, 
Lopinavir/Ritonavir and Nevirapine/Lamivudine/Stavudine was 
detected in the two HIV-1 clinical isolates and the Laboratory strains 
HIV-1IIIB and HIV-1JRFL. The laboratory strain HIV-1IIIB was found to 
be less susceptible to antiretroviral drugs and this could be linked to 
the rapid growth of the strain. The decreased sensitivity noted in 
HIV-1IIIB probably owes to its high replication rate. The findings of 
this study concur with several previous reports that suggested 
similar in vitro susceptibilities to antiretroviral drugs among different 





In this study we have shown that non-B subtype isolates of HIV-1 
are similar in their drug susceptibility to subtype B isolates. These 
findings suggest that the five anti-HIV compounds used in this study 
retain their anti-HIV activity against HIV-1 viral strains other than 
subtype B and continue being useful for the treatment of persons 
infected with non-B HIV-1 subtypes. Similar clinical benefits of 
antiviral therapy could therefore be anticipated in persons infected 
with subtypes of HIV-1 other than subtype B. The major limitations 
in this study are the few viruses studied and the fact that only five 
ARVs were assayed despite the wide spectrum of drugs in the three 
main classes. 
 
What is known about this topic 
• Non-B subtype isolates of HIV-1 are similar in their drug 
susceptibility to subtype B isolates as has been previously 
reported. 
• There are similar clinical benefits of antiviral therapy use 
in persons infected with subtypes of HIV-1 other than 
subtype B. 
 
What this study adds 
• This is the first report of use of a phenotypic assay using 
a cultured virus to asses drug susceptibility of non B 
Kenyan HIV strains 
. 
• This is first report of use of phenotypic assay to evaluate 
generic ARVs widely used in Kenya as well as in many 
other low and middle income countries. 
• The results suggest a biochemical similarity of the reverse 
transcriptase (RT) and protease enzymes from the non B 
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Figure 1: Drug susceptibility curves for AZT, ABC and EFV. LPV/r 
and NVP/3TC/d4T against (A) HIVIIIB, (B) HIV 04RTA, © 
HIV025RTA and HIV-1JRFL (D). Each dilution of the drug was tested in 
duplicate in C8166 cell line for the three X4 viruses and in PBMCs for 
the JRFL (R5). Results represent the means of two independent 
experiments; the figure shows percent inhibition of P24 antigen 
production in culture supernatants. The intersection of horizontal 
broken lines denotes the 50% inhibitory concentration [IC 50] of 
each drug  
 
Figure 2: Inhibition of cytopathic effect [CPE] by the drugs. C8166 
cells were plated in 96-well plates at a concentration of 1x105/ml in 
RPMI1640 culture medium and infected with HIV-1025RTA at a MOI 
of 0.01 and various concentrations of ARVs ranging from 0 to 
5µg/ml added. The micro plates were incubated for 3 to 5 days and 
cells observed daily for CPE under inverted microscope. A and C 
show inhibition of CPE by the ARVs at a concentration of 5µg/ml 
and mock infected control respectively. At 0.04µg/ml drugs 
concentration B a typical CPE of giant multinucleated cells is seen. 
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Figure 1: Drug susceptibility curves for AZT, ABC and EFV. LPV/r and 
NVP/3TC/d4T against (A) HIVIIIB, (B) HIV 04RTA, © HIV025RTA and HIV-1JRFL (D). 
Each dilution of the drug was tested in duplicate in C8166 cell line for the three X4 
viruses and in PBMCs for the JRFL (R5). Results represent the means of two 
independent experiments; the figure shows percent inhibition of P24 antigen 
production in culture supernatants. The intersection of horizontal broken lines 
denotes the 50% inhibitory concentration [IC 50] of each drug  
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Figure 2: Inhibition of cytopathic effect [CPE] by the drugs. C8166 cells were plated in 96-well plates at a concentration of 1x105/ml in RPMI1640 
culture medium and infected with HIV-1025RTA at a MOI of 0.01 and various concentrations of ARVs ranging from 0 to 5µg/ml added. The micro 
plates were incubated for 3 to 5 days and cells observed daily for CPE under inverted microscope. A and C show inhibition of CPE by the ARVs at a 
concentration of 5µg/ml and mock infected control respectively. At 0.04µg/ml drugs concentration B a typical CPE of giant multinucleated cells is 
seen. Magnification x 400 
 
 
 
 
 
 
 
 
 
